title: Treatment of malignant ascites and pleurisy by a streptococcal preparation OK-432 with fresh frozen plasma--a mechanism of polymorphonuclear leukocyte (PMN) accumulation.
abstract: A single injection of a streptococcal preparation, OK-432, with fresh frozen plasma (FFP) (or fresh human serum) into the peritoneal or pleural cavity for the treatment of malignant ascites or pleurisy resulted in a complete reduction of ascitic fluid or pleural effusion in 5 out of 11 patients. FFP was used a further source of complement for the effective accumulation of antitumor polymorphonuclear leukocytes (PMNs) by complement-derived chemotactic factors in the cavity. C5a increased in the fluids 3-9 h after the injection and preceded a massive increase in PMNs. C1 inhibitor (C1INH) and C3b inactivator (C3bINA) decreased in several cases 6 h after the treatment. Chemotactic arachidonic acid metabolites, thromboxane B2(TXB2) as a characteristics of TXA2, and leukotriene B4(LTB4) also increased at the same time even in cases where C5a changed only minimally, and may play a role in accumulating antitumor PMNs in the cavity.
authors.affiliation: First Department of Internal Medicine, Kyoto Prefectural University of Medicine, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Kato
authors.forename: Y
authors.initials: Y
authors.lastname: Yamamura
authors.forename: R
authors.initials: R
authors.lastname: Kin
authors.forename: M
authors.initials: M
authors.lastname: Tanigawa
authors.forename: H
authors.initials: H
authors.lastname: Sano
authors.forename: M
authors.initials: M
authors.lastname: Inoue
authors.forename: S
authors.initials: S
authors.lastname: Sugino
authors.forename: M
authors.initials: M
authors.lastname: Kondo
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001201:Ascites / Q000276:immunology / Q000628:therapy*; D001688:Biological Products / Q000627:therapeutic use*; D003167:Complement Activation; D003182:Complement C5 / Q000032:analysis; D015936:Complement C5a; D005260:Female; D005615:Freezing; D006801:Humans; D007116:Immunization, Passive; D007975:Leukotriene B4 / Q000032:analysis; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000628:therapy*; D009504:Neutrophils / Q000276:immunology*; D010844:Picibanil / Q000009:adverse effects / Q000627:therapeutic use*; D010998:Pleurisy / Q000276:immunology / Q000628:therapy*; D013929:Thromboxane B2 / Q000032:analysis
chemical_list: D001688:Biological Products; D003182:Complement C5; D007975:Leukotriene B4; D010844:Picibanil; D013929:Thromboxane B2; D015936:Complement C5a